Glaucoma is the second leading cause of blindness in the world, mainly induced by increased pressure in the eye. Marijuana has been shown to reduce such pressure, thus benefit glaucoma patients. In this project, we test several components from marijuana extracts that are unlikely to cause psychoactive symptoms, for their therapeutic effects on glaucoma. This […]

Glaucoma is the second leading cause of blindness in the world, mainly induced by increased pressure in the eye. Marijuana has been shown to reduce such pressure, thus benefit glaucoma patients. In the previous project, we screened several individual components from marijuana extracts and tested their ability on keeping cells alive. The current project puts […]

Pain in the craniofacial region is one of the more complex and difficult to treat conditions for patients and clinicians. Current treatments are complicated by limited efficacy and considerable side effects. Many of these conditions show greater prevalence in women than men, but there is a lack of basic research utilizing female animals. Recent advances […]

This project aims toward development of a polymeric delivery system for controlled release of cannabinoids, with application in treatment of patients suffering from glaucoma. InMed Pharmaceuticals is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies with innovative drug delivery systems. So far, two candidates were introduced: CTI-085 is a topical formulation […]